Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

BusinesswireNov 25 08:05 ET

Express News | Contineum Therapeutics Inc - Expects $213.9 Mln Cash to Fund Operations Through 2027

ReutersNov 18 08:05 ET

Express News | Contineum Therapeutics Inc - Phase 1B Study for Pipe-791 to Begin in Q1 2025

ReutersNov 18 08:05 ET

Express News | Contineum Therapeutics Inc: Phase 1B Study for Potential Treatment of Osteoarthritis and Low Back Pain Expected to Commence in Q1 of 2025

ReutersNov 18 08:05 ET

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Business WireNov 18 08:05 ET

Express News | Contineum Therapeutics Expands Clinical Development of Pipe-791 With FDA Authorization of Its Investigational New Drug (Ind) Application for Chronic Pain

ReutersNov 18 08:05 ET